Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic
Best Pharmaceutical Stocks to Buy Now (2026)
Top pharmaceutical stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best pharmaceutical stocks to buy now. Learn More.

Industry: Drug Manufacturers - Spec...
B
Pharmaceutical is Zen Rated B and is the 53rd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Growth
Market Cap
Revenue
EBITDA
Earnings
EPS
Rev. Y/Y
Rev. 5Y
Earn. Y/Y
Earn. 5Y
Earnings Date
BHC
BAUSCH HEALTH COMPANIES INC
$3.20B$11.11B$2.38B-$841.00M-$2.2810.81%5.63%N/AN/A
ETON
ETON PHARMACEUTICALS INC
$1.77B$141.06M$45.77M$49.86M$1.7798.28%52.11%N/AN/A
AMPH
AMPHASTAR PHARMACEUTICALS INC
$1.20B$745.79M$222.86M$98.96M$2.253.11%12.56%-4.66%24.24%
KMDA
KAMADA LTD
$451.68M$196.87M$46.55M$24.95M$0.4312.64%13.68%19.44%33.87%
HCM
HUTCHMED (CHINA) LTD
$2.35B$549.12MN/A$17.88M$0.10-8.81%14.54%-96.30%N/A
ANIP
ANI PHARMACEUTICALS INC
$1.57B$1.04B$257.36M$116.84M$5.1825.94%37.42%202.92%N/A
IRWD
IRONWOOD PHARMACEUTICALS INC
$779.74M$400.30M$261.00M$149.63M$0.9118.09%-0.64%378.95%-22.62%
AMRX
AMNEAL PHARMACEUTICALS INC
$7.45B$3.20B$562.30M$133.30M$0.438.88%9.11%2,050.00%33.87%
NBIX
NEUROCRINE BIOSCIENCES INC
$15.85B$3.70B$1.03B$702.50M$6.9737.98%28.19%61.72%7.88%
ELAN
ELANCO ANIMAL HEALTH INC
$13.14B$5.15B$857.00M-$147.00M-$0.3012.13%1.46%N/AN/A
PAHC
PHIBRO ANIMAL HEALTH CORP
$1.38B$1.54B$235.78M$102.71M$2.5410.10%12.56%52.10%16.18%
TKNO
ALPHA TEKNOVA INC
$491.27M$45.95M-$8.58M-$15.97M-$0.2915.45%4.46%N/AN/A
EOLS
EVOLUS INC
$463.32M$325.47M-$3.02M-$31.11M-$0.4713.87%30.62%N/AN/A
CRON
CRONOS GROUP INC
$1.13B$206.20M$28.31M$57.83M$0.1755.79%25.71%54.55%N/A
HLN
HALEON PLC
$40.51BN/AN/AN/AN/AN/AN/AN/AN/A
TAK
TAKEDA PHARMACEUTICAL CO LTD
$68.40B$29.76B$6.17B$258.58M$0.08-0.19%-0.40%8.45%-43.61%
COLL
COLLEGIUM PHARMACEUTICAL INC
$783.41M$815.19M$122.46M$38.17M$1.217.68%20.13%-34.59%-16.27%
ALKS
ALKERMES PLC
$7.76B$1.75B$178.67M-$351.00k$0.0015.27%9.20%-100.00%N/A
ZTS
ZOETIS INC
$32.83B$9.51B$3.85B$2.49B$5.891.03%4.54%0.00%7.15%
RDY
DR REDDYS LABORATORIES LTD
$12.38B$3.50B$828.17M$446.13M$0.54-1.79%7.67%-27.83%15.15%
CPIX
CUMBERLAND PHARMACEUTICALS INC
$94.47M$25.13M$71.19M$68.80M$4.5910.71%-7.90%N/AN/A
LQDA
LIQUIDIA CORP
$5.10B$621.87M-$88.77M-$94.19M-$1.03798.44%126.73%N/AN/A
PRGO
PERRIGO CO PLC
$2.23B$4.09B-$1.19B-$1.77B-$12.77-4.47%0.02%N/AN/A
OGI
ORGANIGRAM GLOBAL INC
$88.81M$222.11M$76.41M$62.23M$0.4533.27%28.46%N/AN/A2026-12-15
HROW
HARROW INC
$1.21B$303.25M$22.11M-$28.49M-$0.7621.28%35.30%N/AN/A
PBH
PRESTIGE CONSUMER HEALTHCARE INC
$2.35B$1.17B$323.47M$155.10M$3.255.10%2.69%-19.95%-1.86%
SIGA
SIGA TECHNOLOGIES INC
$190.42M$52.36M-$2.03M$686.20k$0.01-69.60%-1.35%-99.04%-45.61%
ALVO
ALVOTECH
$1.53B$494.61M$167.98M-$179.59M-$0.62-12.07%191.35%N/AN/A
APUS
APIMEDS PHARMACEUTICALS US INC
$3.21M$2.90M-$17.30M-$22.74M-$16.04N/AN/AN/AN/A
TRLV
TRULIEVE CANNABIS CORP
$1.60B$1.08B-$118.38M-$445.60M-$2.31-9.09%1.71%N/AN/A
BFRI
BIOFRONTERA INC
$10.23M$48.26M-$4.81M-$6.14M-$0.2529.85%15.47%N/AN/A
DERM
JOURNEY MEDICAL CORP
$100.22M$69.52M$2.78M-$5.10M-$0.1817.03%3.22%N/AN/A
SBFM
SUNSHINE BIOPHARMA INC
$1.94M$35.37M-$5.50M-$6.17M-$170.20-5.23%190.38%N/AN/A
EBS
EMERGENT BIOSOLUTIONS INC
$264.79M$649.10M-$106.60M-$260.70M-$5.01-17.72%-17.26%N/AN/A
IXHL
INCANNEX HEALTHCARE INC
$21.83M$0.00-$14.66M-$14.83M-$1.25-100.00%N/AN/AN/A
GLAS
GLASS HOUSE BRANDS INC
$120.16M$183.18M-$19.07M-$50.02M-$0.716.72%N/AN/AN/A
SXTC
CHINA SXT PHARMACEUTICALS INC
$311.00$41.00-$6.00M-$6.21M-$73.04k-99.05%-86.41%N/AN/A
RGC
REGENCELL BIOSCIENCE HOLDINGS LTD
$2.16B$0.00-$11.30M-$11.70M-$0.02N/AN/AN/AN/A2027-01-06
AKAN
AKANDA CORP
$2.67M$662.47k-$48.75M-$51.04M-$647.62N/AN/AN/AN/A
CRDL
CARDIOL THERAPEUTICS INC
$107.39M$0.00-$26.20M-$26.25M-$0.23N/A-100.00%N/AN/A
AQST
AQUESTIVE THERAPEUTICS INC
$465.67M$48.84M-$63.81M-$79.28M-$0.6512.54%0.81%N/AN/A
TLRY
TILRAY BRANDS INC
$305.92M$963.10M-$48.98M-$164.22M-$1.4115.93%11.31%N/AN/A
SCYX
SCYNEXIS INC
$25.93M$18.88M-$10.10M-$10.10M-$1.44543.96%8.48%N/AN/A
ORGO
ORGANOGENESIS HOLDINGS INC
$102.41M$352.05M-$53.30M-$153.15M-$1.18-24.33%-4.63%N/AN/A
BIOA
BIOAGE LABS INC
$216.46M$8.60M-$107.25M-$107.80M-$2.5545.33%N/AN/AN/A
UPC
UNIVERSE PHARMACEUTICALS INC
$766.14k$17.74M-$1.23M-$1.94M-$1.38-8.04%-14.40%N/AN/A
RMTI
ROCKWELL MEDICAL INC
$24.86M$72.58M-$439.00k-$5.66M-$1.43-3.96%3.28%N/AN/A
GELS
GELTEQ LTD
$3.23M$0.00-$16.30M-$17.36M-$1.60-100.00%N/AN/AN/A
SHPH
SHUTTLE PHARMACEUTICALS HOLDINGS INC
$18.58M$0.00-$8.65M-$10.26M-$17.90N/AN/AN/AN/A
SNOA
SONOMA PHARMACEUTICALS INC
$4.10M$23.49M-$1.27M-$1.80M-$0.9138.69%10.10%N/AN/A
RDHL
REDHILL BIOPHARMA LTD
$0.00-$3.79M-$43.00k-$2.40M$0.00N/AN/AN/AN/A
SUPN
SUPERNUS INC
$3.35B$1.37B$569.00M$450.00M$3.7016.34%N/A259.22%N/A
CPHI
CHINA PHARMA HOLDINGS INC
$21.51M$4.31M-$1.78M-$5.73M-$0.296.38%-14.94%N/AN/A
TLPH
TALPHERA INC
$38.40M$0.00-$14.66M-$14.66M-$0.18-100.00%-100.00%N/AN/A
EVO
EVOTEC SE
$515.20M$807.10MN/A-$203.04M-$0.57-8.36%4.23%N/AN/A
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$44.97B$17.23B$2.43B$506.00M$0.452.71%1.20%-28.57%-7.37%
INCR
INTERCURE LTD
$38.17M$91.56M-$3.91M-$12.10M-$1.1230.37%33.16%N/AN/A
TXMD
THERAPEUTICSMD INC
$20.95M$3.75M$2.04M$122.00k$0.0133.94%-47.15%-50.00%N/A
CGC
CANOPY GROWTH CORP
$200.67M$219.92M-$170.10M-$196.16M-$0.578.18%-13.55%N/AN/A
BGM
BGM GROUP LTD
$58.83M$47.90M-$14.46M-$21.18M-$4.8078.43%-1.71%N/AN/A
YCBD
CBDMD INC
$4.25M$20.93M-$1.18M-$3.08M$0.2410.01%-14.71%N/AN/A2026-12-18
AYTU
AYTU BIOPHARMA INC
$28.91M$58.52M-$14.04M-$20.10M-$1.52-8.12%-4.59%N/AN/A
CABR
CARING BRANDS INC
$7.79M$420.00-$6.82M-$9.68M-$0.74-90.14%N/AN/AN/A
ZYBT
ZHENGYE BIOTECHNOLOGY HOLDING LTD
$72.03M$15.76M-$2.96M-$10.06M-$0.21-27.99%N/AN/AN/A
VTRS
VIATRIS INC
$22.79B$14.73B$2.76B-$607.80M-$0.534.27%-3.02%N/AN/A
IMCC
IM CANNABIS CORP
$767.73k$23.56M-$8.90M-$14.99MN/A-24.69%-1.83%N/AN/A
CTOR
CITIUS ONCOLOGY INC
$52.53M$7.11M-$45.51M-$46.06M-$0.47N/AN/AN/AN/A2026-12-22
ACB
AURORA CANNABIS INC
$280.07M$204.57M-$70.15M-$74.50M-$0.970.76%1.37%N/AN/A
OPTH
OPTIMI HEALTH CORP
$10.02MN/AN/AN/AN/AN/AN/AN/AN/A
LNTH
LANTHEUS HOLDINGS INC
$6.68B$1.56B$453.17M$269.91M$4.152.38%32.00%69.39%N/A
LFCR
LIFECORE BIOMEDICAL INC
$241.46M$127.09M-$25.61M-$73.30M-$1.95N/A-7.87%N/AN/A
PRFX
PRF TECHNOLOGIES LTD
$1.90M$31.00kN/AN/A-$4.22N/AN/AN/AN/A
KALA
KALA BIO INC
$1.94M$0.00-$8.70M-$10.08M-$959.20N/A-100.00%N/AN/A

Pharmaceutical Stocks FAQ

What are the best pharmaceutical stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

1. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the #1 top pharmaceutical stock out of 73 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch Health Companies (NYSE:BHC) is: Value: A, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: C, and AI: C.

Bausch Health Companies (NYSE:BHC) has a Due Diligence Score of 9, which is -20 points lower than the pharmaceutical industry average of 29. Although this number is below the industry average, our proven quant model rates BHC as a "A".

BHC passed 3 out of 33 due diligence checks and has weak fundamentals. Bausch Health Companies has seen its stock return 41.49% over the past year, overperforming other pharmaceutical stocks by 141 percentage points.

Bausch Health Companies has an average 1 year price target of $9.00, an upside of 5.14% from Bausch Health Companies's current stock price of $8.56.

Bausch Health Companies stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Bausch Health Companies, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eton Pharmaceuticals (NASDAQ:ETON)


Eton Pharmaceuticals (NASDAQ:ETON) is the #2 top pharmaceutical stock out of 73 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Eton Pharmaceuticals (NASDAQ:ETON) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: D, Financials: A, and AI: D.

Eton Pharmaceuticals (NASDAQ:ETON) has a Due Diligence Score of 67, which is 38 points higher than the pharmaceutical industry average of 29.

ETON passed 23 out of 33 due diligence checks and has strong fundamentals. Eton Pharmaceuticals has seen its stock return 264.8% over the past year, overperforming other pharmaceutical stocks by 365 percentage points.

Eton Pharmaceuticals has an average 1 year price target of $75.75, an upside of 23.45% from Eton Pharmaceuticals's current stock price of $61.36.

Eton Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Eton Pharmaceuticals, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Amphastar Pharmaceuticals (NASDAQ:AMPH)


Amphastar Pharmaceuticals (NASDAQ:AMPH) is the #3 top pharmaceutical stock out of 73 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Amphastar Pharmaceuticals (NASDAQ:AMPH) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a Due Diligence Score of 50, which is 21 points higher than the pharmaceutical industry average of 29.

AMPH passed 16 out of 33 due diligence checks and has strong fundamentals. Amphastar Pharmaceuticals has seen its stock return 10.8% over the past year, overperforming other pharmaceutical stocks by 111 percentage points.

Amphastar Pharmaceuticals has an average 1 year price target of $22.00, a downside of -21.74% from Amphastar Pharmaceuticals's current stock price of $28.11.

Amphastar Pharmaceuticals stock has a consensus Hold recommendation according to Wall Street analysts. Of the 4 analysts covering Amphastar Pharmaceuticals, 0% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 25% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the pharmaceutical stocks with highest dividends?

Out of 9 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

1. Supernus (NASDAQ:SUPN)


Supernus (NASDAQ:SUPN) has an annual dividend yield of 28.68%, which is 21 percentage points higher than the pharmaceutical industry average of 7.44%.

Supernus's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

2. Cumberland Pharmaceuticals (NASDAQ:CPIX)


Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 23.81%, which is 16 percentage points higher than the pharmaceutical industry average of 7.44%.

Cumberland Pharmaceuticals's dividend payout ratio of 65.4% indicates that its high dividend yield is sustainable for the long-term.

3. Kamada (NASDAQ:KMDA)


Kamada (NASDAQ:KMDA) has an annual dividend yield of 7.15%, which is the same as the pharmaceutical industry average of 7.44%.

Kamada's dividend payout ratio of 97.6% indicates that its high dividend yield might not be sustainable for the long-term.

Why are pharmaceutical stocks down?

Pharmaceutical stocks were down -2.81% in the last day, and down -3.01% over the last week.

We couldn't find a catalyst for why pharmaceutical stocks are down.

What are the most undervalued pharmaceutical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

1. Ironwood Pharmaceuticals (NASDAQ:IRWD)


Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 64 points higher than the pharmaceutical industry average of 22. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 48.11% in the past year. It has overperformed other stocks in the pharmaceutical industry by 148 percentage points.

2. Phibro Animal Health (NASDAQ:PAHC)


Phibro Animal Health (NASDAQ:PAHC) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Phibro Animal Health has a valuation score of 43, which is 21 points higher than the pharmaceutical industry average of 22. It passed 3 out of 7 valuation due diligence checks.

Phibro Animal Health's stock has dropped -17.64% in the past year. It has overperformed other stocks in the pharmaceutical industry by 82 percentage points.

3. Ani Pharmaceuticals (NASDAQ:ANIP)


Ani Pharmaceuticals (NASDAQ:ANIP) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ani Pharmaceuticals has a valuation score of 71, which is 49 points higher than the pharmaceutical industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Ani Pharmaceuticals's stock has dropped -13.94% in the past year. It has overperformed other stocks in the pharmaceutical industry by 86 percentage points.

Are pharmaceutical stocks a good buy now?

55% of pharmaceutical stocks rated by analysts are a strong buy right now. On average, analysts expect pharmaceutical stocks to rise by 189.25% over the next year.

11.11% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 17.78% of pharmaceutical stocks are rated B (Buy), 46.67% are rated C (Hold), 20% are rated D (Sell), and 4.44% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - specialty & generic industry?

The average P/E ratio of the drug manufacturers - specialty & generic industry is 71.75x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.